During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
U = U: The evidence is in. Spreading the word that undetectable = untransmissable is the next crucial step
By Murray Penner of Prevention Access Campaign Undetectable = Untransmittable, or U=U, is a clear, effective, simple way to convey the fact that a person living […]
CDC announces publication of TB treatment trial results showing four month regimen as effective as six month
The publication of trial data showing a four-month treatment regimen for tuberculosis that is not resistant to first-line medicines as effective as the currently widely prescribed […]
By Mitchell Warren, executive director, AVAC In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN […]
By Karen Carvajal, M.D. Over the course of human history we have come a long way in our fight against the threat of infectious diseases and, […]